Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.

Oh JZ, Kurche JS, Burchill MA, Kedl RM.

Blood. 2011 Sep 15;118(11):3028-38. doi: 10.1182/blood-2011-04-348839. Epub 2011 Aug 2.

2.

Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.

Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, Kay T, Smyth MJ, Sadler AJ, Chen W.

J Immunol. 2010 Nov 15;185(10):6013-22. doi: 10.4049/jimmunol.1002129. Epub 2010 Oct 18.

3.

Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.

Kastenmüller K, Wille-Reece U, Lindsay RW, Trager LR, Darrah PA, Flynn BJ, Becker MR, Udey MC, Clausen BE, Igyarto BZ, Kaplan DH, Kastenmüller W, Germain RN, Seder RA.

J Clin Invest. 2011 May;121(5):1782-96. doi: 10.1172/JCI45416. Epub 2011 Apr 11.

4.

Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis.

Roh YS, Park S, Kim JW, Lim CW, Seki E, Kim B.

Hepatology. 2014 Jul;60(1):237-49. doi: 10.1002/hep.26981. Epub 2014 May 27.

5.

TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.

Crespo MI, Zacca ER, Núñez NG, Ranocchia RP, Maccioni M, Maletto BA, Pistoresi-Palencia MC, Morón G.

J Immunol. 2013 Feb 1;190(3):948-60. doi: 10.4049/jimmunol.1102725. Epub 2013 Jan 2.

6.

Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, Reiter Y, Palucka AK, Zurawski G, Banchereau J.

Blood. 2010 Sep 9;116(10):1685-97. doi: 10.1182/blood-2010-01-264960. Epub 2010 Jun 7.

7.

The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity.

Oh JZ, Kedl RM.

J Immunol. 2010 Oct 15;185(8):4602-8. doi: 10.4049/jimmunol.1001892. Epub 2010 Sep 15.

8.

Lymph-borne CD8α+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells.

Cerovic V, Houston SA, Westlund J, Utriainen L, Davison ES, Scott CL, Bain CC, Joeris T, Agace WW, Kroczek RA, Mowat AM, Yrlid U, Milling SW.

Mucosal Immunol. 2015 Jan;8(1):38-48. doi: 10.1038/mi.2014.40. Epub 2014 May 21.

9.

A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.

Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, Bates EE, Trinchieri G, Caux C, Garrone P.

J Exp Med. 2005 May 2;201(9):1435-46. Epub 2005 Apr 25.

10.

Type I IFN-induced, NKT cell-mediated negative control of CD8 T cell priming by dendritic cells.

Bochtler P, Kröger A, Schirmbeck R, Reimann J.

J Immunol. 2008 Aug 1;181(3):1633-43.

11.

A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways.

Xie G, Welte T, Wang J, Whiteman MC, Wicker JA, Saxena V, Cong Y, Barrett AD, Wang T.

Vaccine. 2013 Aug 28;31(38):4143-51. doi: 10.1016/j.vaccine.2013.06.093. Epub 2013 Jul 8.

12.

CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling.

Lindsay RW, Darrah PA, Quinn KM, Wille-Reece U, Mattei LM, Iwasaki A, Kasturi SP, Pulendran B, Gall JG, Spies AG, Seder RA.

J Immunol. 2010 Aug 1;185(3):1513-21. doi: 10.4049/jimmunol.1000338. Epub 2010 Jul 7.

13.

Conventional dendritic cells mount a type I IFN response against Candida spp. requiring novel phagosomal TLR7-mediated IFN-β signaling.

Bourgeois C, Majer O, Frohner IE, Lesiak-Markowicz I, Hildering KS, Glaser W, Stockinger S, Decker T, Akira S, Müller M, Kuchler K.

J Immunol. 2011 Mar 1;186(5):3104-12. doi: 10.4049/jimmunol.1002599. Epub 2011 Jan 31.

14.

Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways.

Seo YJ, Pritzl CJ, Vijayan M, Blake CR, McClain ME, Hahm B.

J Immunol. 2012 May 15;188(10):4759-68. doi: 10.4049/jimmunol.1102754. Epub 2012 Apr 6.

15.

Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.

Forward NA, Furlong SJ, Yang Y, Lin TJ, Hoskin DW.

J Leukoc Biol. 2010 Jan;87(1):117-25. doi: 10.1189/jlb.0908559. Epub 2009 Oct 20.

PMID:
19843574
16.

Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.

Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS.

Blood. 2010 Mar 11;115(10):1949-57. doi: 10.1182/blood-2009-08-238543. Epub 2010 Jan 11.

17.

Activated NKT Cells Can Condition Different Splenic Dendritic Cell Subsets To Respond More Effectively to TLR Engagement and Enhance Cross-Priming.

Osmond TL, Farrand KJ, Painter GF, Ruedl C, Petersen TR, Hermans IF.

J Immunol. 2015 Aug 1;195(3):821-31. doi: 10.4049/jimmunol.1401751. Epub 2015 Jun 15.

18.

Cutting edge: Type I IFN drives emergency myelopoiesis and peripheral myeloid expansion during chronic TLR7 signaling.

Buechler MB, Teal TH, Elkon KB, Hamerman JA.

J Immunol. 2013 Feb 1;190(3):886-91. doi: 10.4049/jimmunol.1202739. Epub 2013 Jan 9.

19.

Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures.

Naik SH, Proietto AI, Wilson NS, Dakic A, Schnorrer P, Fuchsberger M, Lahoud MH, O'Keeffe M, Shao QX, Chen WF, Villadangos JA, Shortman K, Wu L.

J Immunol. 2005 Jun 1;174(11):6592-7.

20.

Supplemental Content

Support Center